Compare HOVR & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | MNOV |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | Canada | United States |
| Employees | 30 | 6 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.6M | 67.9M |
| IPO Year | N/A | 2004 |
| Metric | HOVR | MNOV |
|---|---|---|
| Price | $1.74 | $1.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $10.33 | $7.50 |
| AVG Volume (30 Days) | ★ 1.1M | 72.5K |
| Earning Date | 04-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $180.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $1.16 | $1.17 |
| 52 Week High | $4.18 | $1.96 |
| Indicator | HOVR | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 36.24 | 54.63 |
| Support Level | $1.72 | $1.31 |
| Resistance Level | $1.91 | $1.52 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 11.97 | 43.54 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.